This week, Endpoints News reported on the formation of Medici Therapeutics, a new oncology platform created by ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy through the combination of programs, talent, and intellectual property. Medici builds on the foundation of Marble Therapeutics, a company LongeVC is proud to back since 2023, and reflects a broader shift toward platform-level thinking in cancer drug development.
Medici has also acquired Nutcracker Therapeutics, bringing mRNA manufacturing capabilities in-house. Nutcracker's technology compresses an entire RNA drug manufacturing facility into a printer-sized device using microfluidic biochips, enabling faster and more cost-effective production of personalized RNA medicines compared to traditional methods.
We're proud to support CEO Denitsa Milanova, Matthew Rabinowitz, and the Medici team as they advance oncology drug development.
Read the full article in Endpoints News here.
Medici has also acquired Nutcracker Therapeutics, bringing mRNA manufacturing capabilities in-house. Nutcracker's technology compresses an entire RNA drug manufacturing facility into a printer-sized device using microfluidic biochips, enabling faster and more cost-effective production of personalized RNA medicines compared to traditional methods.
We're proud to support CEO Denitsa Milanova, Matthew Rabinowitz, and the Medici team as they advance oncology drug development.
Read the full article in Endpoints News here.